191 related articles for article (PubMed ID: 12739735)
1. Relapses of hyperthyroidism in patients treated with radioiodine for nodular toxic goiter: relation to thyroid autoimmunity.
Custro N; Ganci A; Scafidi V
J Endocrinol Invest; 2003 Feb; 26(2):106-10. PubMed ID: 12739735
[TBL] [Abstract][Full Text] [Related]
2. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
[TBL] [Abstract][Full Text] [Related]
3. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
[TBL] [Abstract][Full Text] [Related]
4. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
5. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre.
Chiovato L; Santini F; Vitti P; Bendinelli G; Pinchera A
Clin Endocrinol (Oxf); 1994 Jun; 40(6):803-6. PubMed ID: 8033373
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
[TBL] [Abstract][Full Text] [Related]
7. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters.
Huysmans AK; Hermus RM; Edelbroek MA; Tjabbes T; Oostdijk ; Ross HA; Corstens FH; Kloppenborg PW
Thyroid; 1997 Aug; 7(4):535-9. PubMed ID: 9292939
[TBL] [Abstract][Full Text] [Related]
10. Thyroid autoimmunity and thyroid autonomy.
Vitti P; Mariotti S; Marcocci C; Chiovato L; Giachetti M; Fenzi G; Pinchera A
Acta Med Austriaca; 1990; 17 Suppl 1():90-2. PubMed ID: 2202187
[TBL] [Abstract][Full Text] [Related]
11. [The treatment of multinodular large non-toxic goiter using repeated doses of radioiodine (preliminary report)].
Pisarek M; Baczyk M; Gryczyńska M; Sowiński J
Endokrynol Pol; 2007; 58(1):18-26. PubMed ID: 17354201
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
13. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
Chen W; Man N; Li YS; Shan ZY; Teng WP
Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
[TBL] [Abstract][Full Text] [Related]
14. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome.
Erem C; Kandemir N; Hacihasanoglu A; Ersöz HO; Ukinc K; Kocak M
Endocrine; 2004 Oct; 25(1):55-60. PubMed ID: 15545707
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter.
Nygaard B; Jarløv AE; Kristensen LO; Faber J
Horm Metab Res; 2000 Jul; 32(7):283-7. PubMed ID: 10965935
[TBL] [Abstract][Full Text] [Related]
16. Predictors of euthyreosis in hyperthyroid patients treated with radioiodine
Stachura A; Gryn T; Kałuża B; Budlewski T; Franek E
BMC Endocr Disord; 2020 Jun; 20(1):77. PubMed ID: 32487052
[TBL] [Abstract][Full Text] [Related]
17. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
Antonelli A; Rotondi M; Fallahi P; Grosso M; Boni G; Ferrari SM; Romagnani P; Serio M; Mariani G; Ferrannini E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
[TBL] [Abstract][Full Text] [Related]
18. Development of hyperthyroidism in nodular goiter and thyroid malignancies in an area of relatively low iodine intake.
Kristensen HL; Vadstrup S; Knudsen N; Siersbaek-Nielsen K
J Endocrinol Invest; 1995 Jan; 18(1):41-3. PubMed ID: 7759783
[TBL] [Abstract][Full Text] [Related]
19. Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: results of one-year follow-up.
Regalbuto C; Marturano I; Condorelli A; Latina A; Pezzino V
J Endocrinol Invest; 2009 Feb; 32(2):134-8. PubMed ID: 19411811
[TBL] [Abstract][Full Text] [Related]
20. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
